The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes

Journal of Clinical Psychiatry

Volumn 62, Issue SUPPL. 20, 2001, Pages 26-31

  Pettinati, H M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CITALOPRAM; FLUOXETINE; NALTREXONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VIQUALINE; ZIMELDINE;

ALCOHOLISM; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE CLASSIFICATION; DRINKING BEHAVIOR; DRUG EFFECT; DRUG RESPONSE; DRUG USE; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; PREDICTION; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM;

ALCOHOLISM; CLINICAL TRIALS; COMORBIDITY; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FLUOXETINE; HUMANS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0034804060     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Use of serotonin selective pharmacotherapy in the treatment of alcohol dependence
2. Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence
3. Serotonergic studies in patients with affective and personality disorders: Correlates with suicidal and impulsive aggressive behavior
4. The serotonin hypothesis of major depression
5. Tryptophan depletion and aggressive responding in healthy males
6. Use of serotonin (5-hydroxytryptamine) reuptake inhibitors in the treatment of alcoholism
7. Effects of ethanol on neurotransmitter release by rat brain cortical
8. 3 receptor-mediated ion current in NCB-20 neuroblastoma cells
9. Ondansetron alters human alcohol intoxication
10. Ethanol enhances the release of dopamine and serotonin in the nucleus accumbens of HAD and LAD lines of rats
11. Factors influencing monoamine metabolites and tryptophan in patients with alcohol dependence
12. The serotonin reuptake inhibitor sertraline reduces excessive alcohol consumption in nonhuman primates: Effect of stress
13. Serotonin-sub (2C) receptors and serotonin-sub (2C) receptor-mediated phosphoinositide hydrolysis in the brain of alcohol-preferring rats
14. CSF studies on alcoholism and related behaviours
15. 3 receptor antagonists block morphine- and nicotine- but not amphetamine-induced reward
16. 5-HT receptors: Implications for the neuropharmacology of alcohol and alcoholism
17. 2A antagonists amperozide and FG5974
18. 2A receptor antagonists reduce alcohol intake in three strains of alcohol-preferring rats
19. Effects of amperozide, 8-OH-DPAT, and FG 5974 on operant responding for ethanol
20. Age of alcoholism onset, 1: Relationship to psychopathology
21. Age of alcoholism onset, 2: Relationship to susceptibility to serotonin precursor availability
22. Reduced central serotonin transporters in alcoholism
23. Implications of recent neuropsychopharmacologic research for understanding the etiology and development of alcoholism
24. Relationships of plasma tryptophan availability to course of illness and clinical features of alcoholism: A preliminary study
25. Brain serotonin, type II alcoholism and impulsive violence
26. Ethanol stimulates the firing rate of nigral dopaminergic neurons in unanesthesized rats
27. The neurobiology of craving: Implications for the understanding and treatment of addiction
28. Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers
29. The serotonin uptake inhibitor citalopram attenuates ethanol intake
30. Differential effects of viqualine on alcohol intake and other consummatory behaviors
31. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers
32. Effect of fluoxetine on alcohol consumption in male alcoholics
33. A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: Adjunctive pharmacotherapy during and after inpatient treatment
34. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics
35. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics
36. Sertraline treatment for alcohol dependence: Interactive effects of medication and subtype
37. Comorbidity of mental disorders with alcohol and other drug abuse: Results from the Epidemiologic Catchment Area (ECA) study
38. The epidemiology of co-occurring addictive and mental disorders: Implications for prevention and service utilization
39. Comorbidity between DSM-IV alcohol use disorders and major depression: Results of a national survey
40. Gender and psychiatric comorbidity: Impact on clinical presentation of alcohol dependence
41. Preliminary report: Double-blind, placebo-controlled study of fluoxetine in depressed alcoholics
42. Fluoxeline in depressed alcoholics: A double-blind, placebo-controlled trial
43. Placebo-controlled study of sertraline in depressed recently abstinent alcoholics
44. Double-blind clinical trial of sertraline treatment for alcohol dependence
45. A placebo-controlled trial of buspirone in anxious inpatient alcoholics
46. Buspirone in the treatment of alcohol dependence: A placebo-controlled trial
47. Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone)
48. Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
49. Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence
50. Types of alcoholics, 1: Evidence for an empirically derived typology based on indicators of vulnerability and severity
51. Age of onset as a discriminator between alcoholic subtypes in treatment-seeking outpatient populations
52. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: From hypotheses to preliminary clinical evidence
53. Ethanol-like properties of the serotonergic partial agonist m-chlorophenylpiperazine in chronic alcoholic patients
54. Early-onset alcoholics have lower cerebrospinal fluid 5-hydroxyindoleacetic acid levels than late-onset alcoholics
55. Specificity of ethanol-like effects elicited by serotonergic and noradrenergic mechanisms
56. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects
57. Neuroendocrine responses to serotonergic agents in alcoholics
58. Neurogenetic adaptive mechanisms in alcoholism
59. Unitary versus multidimensional models of alcoholism treatment outcome: An empirical study
60. Types of alcoholics: Concurrent and predictive validity of some common classification schemes
61. Clinical importance of age at onset in type 1 and type 2 primary alcoholics
62. CSF tryptophan and transmitter amine turnover may predict social behaviour in the normal rat
63. Plasma insulin, tryptophan and serotonin levels during the glucose tolerance test among habitually violent and impulsive offenders
64. Major depressive disorder, alcoholism, and reduced natural killer cell cytotoxicity: Role of severity of depressive symptoms and alcohol consumption
65. Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients
66. Naltrexone and alcohol dependence: Role of subject compliance
67. Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients
68. Occurrence and management of depression in the context of naltrexone treatment of alcoholism
69. Combination pharmacotherapy in alcoholism: A novel treatment approach
70. Naltrexone utility in depressed alcoholics
71. Sertraline with naltrexone vs naltrexone alone in the treatment of alcohol dependence
72. Combination pharmacotherapy in nalmefene nonresponders